GLP-1 Microdosing FAQ: Cost, Eligibility, and How It Works

What is GLP-1 microdosing?

GLP-1 microdosing refers to using GLP-1 medications at lower doses than those used in active weight loss treatment, often below the labeled maintenance doses. It is not an FDA-approved designation or formal protocol. The term has emerged from both patient communities and healthcare providers to describe a lower-dose, longer-term approach to ongoing metabolic support and weight maintenance. Ongoing use below the labeled maintenance doses is off-label, and there is little trial evidence for it.

The key distinction is that microdosing is primarily for maintenance, not for initiating weight loss. People using this approach have typically reached their goal weight and want to sustain it with fewer of the side effects that can occur at higher doses.

Who is microdosing for?

Lower-dose maintenance is usually discussed for people with prior GLP-1 experience who want to maintain weight loss long-term: people who have already completed active treatment with a GLP-1 medication. It is not usually a starting point for someone new to GLP-1 medications.

Prior experience matters because you already know how your body responds to GLP-1 treatment: your tolerance, your side effects, and which dose levels worked for you. That history gives you and a provider something to work from.

At most telehealth programs, a licensed provider reviews your health history, prior treatment experience, and current health metrics, and decides whether a prescription, and at what dose, is appropriate. Criteria differ from program to program, so ask the provider you are considering how they decide.

What dose is considered a microdose?

There is no official FDA definition for microdosing. Start with the label facts. For semaglutide for weight management (Wegovy), the FDA label lists 2.4mg weekly as the usual maintenance dose and 1.7mg as an alternative, and the current label allows some people to increase to a maximum of 7.2mg weekly.^[5] For tirzepatide (Zepbound), the label lists 5mg, 10mg, or 15mg weekly as maintenance doses; 2.5mg is a starting dose only.^[6]

After goal weight, some providers use lower semaglutide doses, roughly 0.5mg to 1.7mg weekly, and sometimes 0.25mg to 0.5mg. For tirzepatide, some providers use 2.5mg to 7.5mg weekly. Doses below 1.7mg of semaglutide, ongoing 2.5mg of tirzepatide, and other doses below the labeled maintenance doses are off-label, with little trial evidence behind them. The exact dose depends on your prior treatment, your current weight, and what the provider you choose decides is appropriate.

For dose reference ranges and more detail on which doses are on the label, see the microdosing chart.

Is microdosing safe long-term?

Long-term safety data for GLP-1 medications for weight management come mainly from trials of full doses. The SELECT trial enrolled 17,604 adults with cardiovascular disease and overweight or obesity and followed them on semaglutide 2.4mg or placebo for a mean of about 40 months.^[1] The STEP 4 and SURMOUNT-4 maintenance trials also kept people on their full dose: semaglutide 2.4mg in STEP 4, and the maximum tolerated tirzepatide dose of 10 or 15mg in SURMOUNT-4.^[2][4] None of these trials tested long-term use of doses below the labels.

There is no established 10+ year safety data yet for any GLP-1 medication, whether at full dose or a lower dose, and the medications’ warnings apply at any dose. This is why ongoing monitoring with a provider is important. Ask the provider you choose how they will follow your side effects, labs, and overall health over time.

Will I regain weight if I stop microdosing?

For many people, yes. In the STEP 1 trial extension, adults who stopped semaglutide 2.4mg after 68 weeks regained about two-thirds of the weight they had lost within a year.^[3] In STEP 4, people switched to placebo after a 20-week semaglutide run-in regained an average of 6.9% of body weight over the next 48 weeks, while those who continued lost a further 7.9%.^[2] SURMOUNT-4 found a similar pattern with tirzepatide: people switched to placebo regained 14.0% of body weight over a year, while those who stayed on their maximum tolerated dose lost a further 5.5%.^[4] Results vary, and trial results describe study participants, not a prediction for any individual.

Whether you continue, reduce, or stop your medication is an individual clinical decision that you and your provider make together based on your goals, your health metrics, and how you feel on the medication. There is no single right answer here. Some people choose to continue indefinitely. Others decide the tradeoff is not worth it. A provider can help you think through your specific situation.

Is microdosing covered by insurance?

It depends on the medication and your plan. Compounded GLP-1 medications are generally cash-pay and not billed to insurance. Coverage for brand-name products for weight management varies widely by plan, and plans that do cover them may require prior authorization. Ask your insurer how they handle the specific medication and dose, and ask any program you are considering whether it bills insurance.

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.

How much does microdosing cost?

Prices vary by program, medication, and dose. Some programs price by dose, so a lower dose may cost less; others charge a flat fee whatever the dose. Compare the total cost, not the headline number:

• The medication itself, and whether the price changes when your dose goes down
• Provider visits and follow-ups during maintenance
• Lab work, and whether it is included or billed separately
• Coaching or nutrition support, if you want it, and whether it costs extra
• Shipping, membership fees, and cancellation terms

Does microdosing still help with appetite?

It can. GLP-1 medications reduce appetite and slow gastric emptying, and those effects are generally weaker at lower doses. Some people report that a lower dose is enough to keep their weight steady and food noise manageable; others find it is not enough and need a higher dose. There is little trial evidence on how well doses below the labels maintain weight.

Think of it as tuning the volume down rather than turning it off completely. Results vary, and how a lower dose works for you is something to track with your provider.

Program options to review

When you compare programs for maintenance, look at four things: goal, dose, cost, and who the program is for.

Goal: Some programs focus on active weight loss. Others offer a separate maintenance option for people who have reached their goal weight.

Dose: Active-treatment plans step the dose up toward the labeled maintenance doses. Maintenance plans may keep you at a labeled maintenance dose or step it down; anything below the labeled maintenance doses is off-label.

Cost: Some programs charge less for lower doses or maintenance plans, and some do not. Compare the total cost, including medication, visits, labs, shipping, membership fees, and cancellation terms.

Who it is for: Lower-dose maintenance is generally for people with prior GLP-1 experience. If you are just starting out on a GLP-1 medication, a provider would usually begin with the labeled dose-escalation schedule.

Transformation Health does not accept payment from providers. How we make money.

Can I switch from full dose to microdose?

Some people do, but it is a clinical decision, not a routine step. The labels list maintenance doses rather than a step-down schedule, and the main maintenance trials kept people on their full dose. When a provider does reduce a dose, it is usually done gradually, in steps over time rather than all at once.

The provider you choose decides whether to step down and on what schedule, based on how you are feeling, your appetite, and your weight stability. Some people step down over a few weeks; others more gradually, and some find they need to stay at a labeled maintenance dose. Do not change your dose on your own.

Does microdosing help with things other than weight maintenance?

Research is exploring GLP-1 medications for inflammation and other conditions, but those are not approved uses. Some approved uses beyond weight management exist at full doses: the Wegovy label includes reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on 2.4mg.^[1][5] Those approvals do not extend to lower off-label doses or to compounded medications. For more on what the research does and does not show, see microdosing for inflammation and autoimmune conditions.

If you are interested in whether a GLP-1 medication might help with other health goals beyond weight, discuss this with your provider. They can evaluate your specific situation and advise you based on your health history and the current evidence.

What labs do I need on microdosing?

That depends on your health history and on the provider you choose. Some providers check a metabolic panel, HbA1c, and lipid panel at set points; others order labs only when there is a specific reason. Lab frequency during maintenance varies, often every few months to once a year, depending on the provider’s assessment and your health profile.

Some programs include labs in their price and others bill for them separately, so ask how labs are handled, and where you would have them drawn, before you start.

Transformation Health is relaunching as an independent GLP-1 guide with a free custom report that compares programs. Leave your email to be told when the report is available.

Citations

[1] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/

[2] Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/

[3] Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes Obes Metab 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

[4] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/

[5] Novo Nordisk. WEGOVY (semaglutide) prescribing information, sections 1 and 2. Revised 06/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[6] Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information, sections 2.1 and 2.2. Revised 08/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf